Zalicus (NASDAQ: ZLCS) posted its quarterly earnings results on Wednesday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $3.67 million for the quarter, compared to the consensus estimate of $3.12 million.
On a related note, analysts at Piper Jaffray initiated coverage on shares of Zalicus in a research note to investors on Thursday, January 3rd. They set a “neutral” rating on the stock.
Two research analysts have rated the stock with a buy rating, and one has issued a hold rating to the company. Zalicus currently has an average rating of “overweight” and an average target price of $2.00.
Shares of Zalicus (ZLCS) opened at 0.64 on Wednesday. Zalicus (ZLCS) has a one year low of $0.43 and a one year high of $1.62. The stock’s 50-day moving average is currently $0.68. The company’s market cap is $81.0 million.
Zalicus Inc., formerly CombinatoRx, Incorporated, is a biopharmaceutical company engaged in developing drug candidates with a focus on the treatment of pain and inflammation.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.